IQWiG reports a hint of considerable added benefit for trastuzumab deruxtecan in advanced HER2-positive gastric or GEJ adenocarcinoma

On 19 March 2026, IQWiG published dossier assessment A25-128 and reported a hint of considerable added benefit for trastuzumab deruxtecan versus ramucirumab plus paclitaxel in previously trastuzumab-treated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma, based on direct randomised evidence from DESTINY-Gastric04.